Compare BMY & BAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMY | BAM |
|---|---|---|
| Founded | 1887 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.0B | 87.2B |
| IPO Year | N/A | N/A |
| Metric | BMY | BAM |
|---|---|---|
| Price | $50.82 | $53.99 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 10 |
| Target Price | $55.58 | ★ $63.38 |
| AVG Volume (30 Days) | ★ 15.1M | 3.1M |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | ★ 4.80% | 3.29% |
| EPS Growth | N/A | ★ 42.52 |
| EPS | ★ 2.97 | 1.62 |
| Revenue | ★ $48,034,000,000.00 | $4,486,000,000.00 |
| Revenue This Year | $0.23 | $34.55 |
| Revenue Next Year | N/A | $14.64 |
| P/E Ratio | ★ $17.39 | $32.82 |
| Revenue Growth | 1.26 | ★ 10.85 |
| 52 Week Low | $42.52 | $41.78 |
| 52 Week High | $63.33 | $64.10 |
| Indicator | BMY | BAM |
|---|---|---|
| Relative Strength Index (RSI) | 63.47 | 56.43 |
| Support Level | $48.22 | $52.19 |
| Resistance Level | $52.51 | $54.15 |
| Average True Range (ATR) | 1.13 | 1.09 |
| MACD | 0.29 | 0.43 |
| Stochastic Oscillator | 77.92 | 93.43 |
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Brookfield Asset Management Ltd engages in providing alternative asset management services through an ownership interest in a alternative asset management business. It offers a range of alternative investment products to investors around the world including public and private pension plans, endowments and foundations, sovereign wealth funds, financial institutions, insurance companies, and private wealth investors.